Midlife vascular risk factors and late-life mild cognitive impairment
A population-based study
Abstract
Objective: To evaluate the impact of midlife elevated serum cholesterol levels and blood pressure on the subsequent development of mild cognitive impairment (MCI) and to investigate the prevalence of MCI in elderly Finnish population, applying the MCI criteria devised by the Mayo Clinic Alzheimer’s Disease Research Center.
Background: MCI has been considered as a predictor of AD. Vascular risk factors may be important in the development of cognitive impairment and AD. However, the role of vascular risk factors in MCI and the prevalence of MCI still remain virtually unknown.
Methods: Subjects were derived from random, population-based samples previously studied in surveys carried out in 1972, 1977, 1982, and 1987. After an average follow-up of 21 years, 1,449 subjects aged 65 to 79 years were reexamined in 1998.
Results: Eighty-two subjects, 6.1% of the population (average age, 72 years) met the criteria for MCI. Midlife elevated serum cholesterol level (≥6.5 mmol/L) was a significant risk factor for MCI (OR, 1.9; 95% CI, 1.2 to 3.0, adjusted for age and body mass index); the effect of systolic blood pressure approached significance.
Conclusion: Data point to a role for midlife vascular risk factors in the development of MCI in late life.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment. Arch Neurol . 1999; 56: 303–308.
2.
Viitanen M, Guo Z. Are cognitive function and blood pressure related? Drugs Aging . 1997; 11: 165–169.
3.
Breteler MM, Bots ML, Ott A, et al. Risk factors for vascular disease and dementia. Haemostasis . 1998; 28: 167–173.
4.
Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet . 1996; 347: 1141–1145.
5.
Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging . 2000; 21: 49–55.
6.
Kivipelto M, Helkala E-L, Hallikainen M, et al. Elevated systolic blood pressure and high cholesterol levels at midlife are risk factors for late-life dementia. Neurobiol Aging . 2000; 21 (suppl 1): S174.Abstract.
7.
Launer LJ, Masaki K, Petrovitch H, et al. The association between midlife blood pressure levels and late-life cognitive function. JAMA . 1995; 274: 1846–1851.
8.
Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment; a 20-year follow-up of 999 men. Hypertension . 1998; 31: 780–786.
9.
Elias MF, Wolf PA, D’Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol . 1993; 138: 353–364.
10.
Carmelli D, Swan GE, Reed T, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology . 1998; 50: 1580–1585.
11.
Glynn RJ, Beckett LA, Hebert LE, et al. Current and remote blood pressure and cognitive decline. JAMA . 1999; 281: 438–445.
12.
Notkola I-L, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E 4, and Alzheimer’s disease. Neuroepidemiology . 1998; 17: 14–20.
13.
Braak E, Griffing K, Arai K, et al. Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci . 1999; 249 (suppl 3): 14–22.
14.
Smith GE, Petersen RC, Parisi JE, et al. Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cogn . 1996; 3: 141–147.
15.
Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of development of Alzheimer’s disease in memory-impaired individuals. JAMA . 1995; 273: 1274–1278.
16.
Vartiainen E, Puska P, Jousilahti P, et al. Twenty-year trends in coronary risk factors in North-Karelia and in other areas of Finland. Int J Epidemiology . 1994; 23: 495–504.
17.
Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res . 1975; 12: 189–198.
18.
Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology . 1974; 24: 1019–1025.
19.
Wechsler D. Wechsler Memory Scale–Revised manual. San Antonio: The Psychological Corporation, 1987.
20.
Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Philadelphia: Lea and Febiger, 1983.
21.
Wechsler D. WAIS-R Manual. New York: Psychological Corporation, 1981.
22.
Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia . 1967; 5: 135–140.
23.
Goodglass H, Kaplan E. The assessment of aphasia and related disorders. Philadelphia: Lea and Febiger, 1972.
24.
Nelson HE. A modified card sorting test sensitive to frontal lobe defects. Cortex . 1976; 12: 313–324.
25.
Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills . 1958; 8: 271–276.
26.
Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull . 1988; 24: 637–639.
27.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: American Psychiatric Association, 1994.
28.
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology . 1984; 34: 939–944.
29.
Launer LJ, Wind WA, Deeg DJH. Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly. Am J Epidem . 1994; 139: 803–812.
30.
Skoog I, Kalaria RN, Breteler MMB. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord . 1999; 13 (suppl 3): 106–114.
31.
Carmelli D, Swan GE, Reed T, et al. Midlife cardiovascular risk factors and brain morphology in identical older male twins. Neurology . 1999; 12: 1119–1124.
32.
Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med . 1995; 323: 512–521.
33.
Bodovitz S, Klein WL. Cholesterol modulates α-secretase cleavage of amyloid precursor protein. J Biol Chem . 1996; 271: 4436–4440.
34.
Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A . 1998; 95: 6460–6464.
35.
Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health . 1998; 88: 1337–1342.
Information & Authors
Information
Published In
Copyright
© 2001.
Publication History
Received: October 10, 2000
Accepted: February 13, 2001
Published online: June 26, 2001
Published in print: June 26, 2001
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- The Relation Between Arterial Hypertension and Cognitive Impairment: A Literature Review, Cureus, (2024).https://doi.org/10.7759/cureus.52782
- The Role of Copper in Alzheimer’s Disease Etiopathogenesis: An Updated Systematic Review, Toxics, 12, 10, (755), (2024).https://doi.org/10.3390/toxics12100755
- Standard and New Echocardio Techniques, Such as Global Longitudinal Strain, to Monitor the Impact of Diets on Cardiovascular Diseases and Heart Function, Nutrients, 16, 10, (1471), (2024).https://doi.org/10.3390/nu16101471
- Hypertension, Cognitive Decline, and Mild Cognitive Impairment Among Diverse Hispanics/Latinos: Study of Latinos-Investigation of Neurocognitive Aging Results (SOL-INCA), Journal of Alzheimer's Disease, 97, 3, (1449-1461), (2024).https://doi.org/10.3233/JAD-230424
- Non-linear relationship between serum cholesterol levels and cognitive change among older people in the preclinical and prodromal stages of dementia: a retrospective longitudinal study in Taiwan, BMC Geriatrics, 24, 1, (2024).https://doi.org/10.1186/s12877-024-05030-0
- The association between serum cholesterol levels and mild-to-moderate cognitive impairment in the Suita Study and evidence from other epidemiological studies, Journal of the Neurological Sciences, 466, (123244), (2024).https://doi.org/10.1016/j.jns.2024.123244
- Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence, Current Atherosclerosis Reports, 27, 1, (2024).https://doi.org/10.1007/s11883-024-01255-x
- Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment, ESC Heart Failure, (2024).https://doi.org/10.1002/ehf2.15144
- Statins’ Effects on Alzheimer’s Disease, Statins - From Lipid-Lowering Benefits to Pleiotropic Effects, (2023).https://doi.org/10.5772/intechopen.1001286
- Cognitive Decline in Early and Premature Menopause, International Journal of Molecular Sciences, 24, 7, (6566), (2023).https://doi.org/10.3390/ijms24076566
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.